<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05067270</url>
  </required_header>
  <id_info>
    <org_study_id>18278</org_study_id>
    <secondary_id>I8B-MC-ITTC</secondary_id>
    <secondary_id>2021-001987-18</secondary_id>
    <nct_id>NCT05067270</nct_id>
  </id_info>
  <brief_title>A Study of Infusion Site Pain After Infusion of Excipients in Participants With Type 1 Diabetes Mellitus</brief_title>
  <official_title>A Study to Investigate Local Infusion Site Pain After Infusion of Excipients Across Infusion Sites and Infusion Depths</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the effect of excipients sodium citrate and&#xD;
      treprostinil without insulin on local infusion site pain in participants with type 1 diabetes&#xD;
      mellitus (T1DM) on continuous subcutaneous insulin infusion (CSII). The study may last up to&#xD;
      36 days including a screening period and 3 visits.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2021</start_date>
  <completion_date type="Anticipated">December 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analog Scale (VAS) Pain Score</measure>
    <time_frame>Day 1: Within 1 minute post dose</time_frame>
    <description>The Infusion site pain VAS score is a participant administered single item scale designed to measure pain using a 0-100 millimeter (mm) horizontal VAS. Overall severity of participant's pain is indicated by placing a single mark on the horizontal 100 mm scale from 0 mm (no pain) to 100 mm (worst imaginable pain).</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Sodium citrate and Treprostinil (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive sodium citrate and treprostinil in Humalog diluent with magnesium chloride (without insulin) as subcutaneous (SC) infusion using Medtronic™ MiniMed™ 770G pump</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium citrate (Part B - Test 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive sodium citrate in Humalog diluent with magnesium chloride (without insulin) as SC infusion using Medtronic™ MiniMed™ 770G pump</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treprostinil (Part B - Test 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive treprostinil in Humalog diluent with magnesium chloride (without insulin) as SC infusion using Medtronic™ MiniMed™ 770G pump</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium citrate and Treprostinil (Part B - Test 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive sodium citrate and treprostinil in Humalog diluent with magnesium chloride (without insulin) as SC infusion using Medtronic™ MiniMed™ 770G pump</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Humalog diluent (Part B - Test 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive Humalog diluent (without insulin) as SC infusion using Medtronic™ MiniMed™ 770G pump</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Citrate</intervention_name>
    <description>Administered SC infusion.</description>
    <arm_group_label>Sodium citrate (Part B - Test 1)</arm_group_label>
    <arm_group_label>Sodium citrate and Treprostinil (Part A)</arm_group_label>
    <arm_group_label>Sodium citrate and Treprostinil (Part B - Test 3)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treprostinil</intervention_name>
    <description>Administered SC infusion.</description>
    <arm_group_label>Sodium citrate and Treprostinil (Part A)</arm_group_label>
    <arm_group_label>Sodium citrate and Treprostinil (Part B - Test 3)</arm_group_label>
    <arm_group_label>Treprostinil (Part B - Test 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Humalog diluent</intervention_name>
    <description>Administered SC infusion.</description>
    <arm_group_label>Humalog diluent (Part B - Test 4)</arm_group_label>
    <arm_group_label>Sodium citrate (Part B - Test 1)</arm_group_label>
    <arm_group_label>Sodium citrate and Treprostinil (Part A)</arm_group_label>
    <arm_group_label>Sodium citrate and Treprostinil (Part B - Test 3)</arm_group_label>
    <arm_group_label>Treprostinil (Part B - Test 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium Chloride</intervention_name>
    <description>Administered SC infusion.</description>
    <arm_group_label>Sodium citrate (Part B - Test 1)</arm_group_label>
    <arm_group_label>Sodium citrate and Treprostinil (Part A)</arm_group_label>
    <arm_group_label>Sodium citrate and Treprostinil (Part B - Test 3)</arm_group_label>
    <arm_group_label>Treprostinil (Part B - Test 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medtronic™ MiniMed™ 770G pump</intervention_name>
    <description>Used to administer drug through SC infusion.</description>
    <arm_group_label>Humalog diluent (Part B - Test 4)</arm_group_label>
    <arm_group_label>Sodium citrate (Part B - Test 1)</arm_group_label>
    <arm_group_label>Sodium citrate and Treprostinil (Part A)</arm_group_label>
    <arm_group_label>Sodium citrate and Treprostinil (Part B - Test 3)</arm_group_label>
    <arm_group_label>Treprostinil (Part B - Test 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  T1D for at least 1 year and continuously using insulin for at least 1 year&#xD;
&#xD;
          -  Using an insulin pump for at least the last 6 months&#xD;
&#xD;
          -  Have hemoglobin A1c (HbA1c) value of ≤ 9.0%&#xD;
&#xD;
          -  Have a body mass index (BMI) within the range of 18.5 to 35.0 kilograms per square&#xD;
             meter (kg/m²)&#xD;
&#xD;
          -  Have medical and laboratory test results that are acceptable for the study&#xD;
&#xD;
          -  Have venous access sufficient to allow for blood sampling&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hemophilia or any other bleeding disorder&#xD;
&#xD;
          -  Have a pathologic tuning fork test as assessed with a Rydel-Seiffer tuning fork&#xD;
&#xD;
          -  Are taking anesthetics or pain medication regularly or intermittently which could&#xD;
             interfere with interpretation of pain scale&#xD;
&#xD;
          -  Have had more than 1 episode of severe hypoglycemia (defined as requiring assistance&#xD;
             due to neurologically disabling hypoglycemia) within the last 90 days prior to&#xD;
             screening&#xD;
&#xD;
          -  Have had more than 1 emergency room visit or hospitalization due to poor glucose&#xD;
             control (hyperglycemia or diabetic ketoacidosis) within the last 6 months prior to&#xD;
             screening&#xD;
&#xD;
          -  Have any hypersensitivity or allergy to any of the diluents or excipients used in this&#xD;
             trial&#xD;
&#xD;
          -  Have or used to have health problems or medical test results that, in the opinion of&#xD;
             the doctor, could make it unsafe to participate, or could interfere with understanding&#xD;
             the results of the study&#xD;
&#xD;
          -  Have participated, within the last 30 days, in a clinical trial involving an&#xD;
             investigational product&#xD;
&#xD;
          -  Have used or are currently using Lyumjev® as part of their standard insulin therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@Lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Profil Institut für Stoffwechselforschung</name>
      <address>
        <city>Neuss</city>
        <state>Nordrhein-Westfalen</state>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+49 2131 4018 408</phone>
    </contact>
    <investigator>
      <last_name>Marc Sebastian Stoffel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Profil Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55116</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+49 6131 2162 609</phone>
    </contact>
    <investigator>
      <last_name>Marcel Ermer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 28, 2021</study_first_submitted>
  <study_first_submitted_qc>September 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Humalog - Insulin lispro</keyword>
  <keyword>Citrate</keyword>
  <keyword>Infusion Site Pain</keyword>
  <keyword>Excipients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Lispro</mesh_term>
    <mesh_term>Treprostinil</mesh_term>
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Sodium Citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

